TRW KNOWLEDGE · LEGAL INFORMATION
Drugs and Cosmetics Law in Bangladesh: Legal Overview and Practical Compliance Guide
An accessible guide to the regulatory framework that governs manufacture, import, export, distribution and sale of drugs and cosmetics in Bangladesh, summarising key statutes, licensing pathways, import-export controls, enforcement risks and practical steps for compliance.
Introduction
This guide summarises the legal framework that governs drugs and cosmetics in Bangladesh and outlines practical compliance steps for businesses, importers, manufacturers, distributors and advisers. It draws on the statutory framework commonly referenced in practice — including the Drugs Act 1940 and the associated rules and orders that remain central to regulation — and explains how import-export controls, licensing procedures, quality control and dispute resolution typically interact in this sector. The content below is a synthesis of commonly cited legal instruments and practical issues; where specifics are required for a particular product, transaction or regulatory filing, readers should consult the relevant authorities or obtain tailored legal advice.Core legislative and policy framework
The regulatory backbone for drugs and cosmetics in Bangladesh is the Drugs Act 1940, supported by subordinate measures such as the Drugs (Control) Ordinance and the Drugs (Control) Rules 1982. Trade in these goods is also governed by national import and export policy instruments — notably the Import Policy Order 2021-2024 and the Export Policy 2024-2027 — which address the terms on which pharmaceutical and cosmetic goods may be brought into or shipped from Bangladesh. Other routinely referenced statutes and instruments that intersect with the sector include the Customs Act 1969, the Foreign Exchange Regulation Act 1947 and the Bank Company Act 1991. Documentary trade practices such as UCP 600 and URDG 758 and commercial allocation tools such as INCOTERMS 2020 are often used by market participants to structure payments and logistics.Regulatory authorities and roles
The Directorate General of Drug Administration (DGDA) is the principal national regulator responsible for licensing, product registration, quality control and enforcement under the drugs and cosmetics regime. For import-export operations, the National Board of Revenue (NBR) and Bangladesh Customs carry out customs assessment and clearance functions. Disputes arising under these laws or in commercial relations related to drugs and cosmetics may ultimately be litigated before domestic courts, including the Bangladesh Supreme Court, or addressed through contractual dispute resolution mechanisms agreed by the parties.Licensing: who needs a licence and common categories
Engaging in manufacture, import, wholesale distribution or retail sale of drugs and many cosmetic products ordinarily requires licences issued or registered with the DGDA. The licensing regime is structured by activity and typically includes manufacturing licences, import licences and licences for wholesale and retail distribution. Applications are usually accompanied by documentation demonstrating premises, technical capacity, personnel qualifications and compliance with Good Manufacturing Practices (GMP) where applicable. Below is a practical summary of common licence categories and the principal documentary or operational themes that accompany them.| Licence Type | Applicable Sector | Key documentary or operational requirements (typical) | Issuing authority |
|---|---|---|---|
| Manufacturing licence | Drug and cosmetic manufacturers | Facility inspection, evidence of GMP compliance, qualified technical staff | Directorate General of Drug Administration (DGDA) |
| Import licence | Importers of drugs and cosmetics | Product registration, import documentation, compliance with Import Policy Order | DGDA and Bangladesh Customs |
| Wholesale licence | Wholesale distributors | Proper storage facilities, record-keeping systems | DGDA |
| Retail licence | Pharmacies and cosmetic retailers | Qualified pharmacist or competent person on staff, appropriate storage | DGDA |
Product registration and quality control
Before marketing a drug or many cosmetic products, product registration with the DGDA is generally required. Registration dossiers typically set out composition, excipient details, safety information and any relevant clinical or analytical data where applicable. Labels and marketing materials should meet statutory and regulatory labelling requirements in force.The DGDA conducts quality control testing and post-market surveillance to identify counterfeit, substandard or unsafe products. When regulatory action follows — for example product seizure or recall — the DGDA’s enforcement powers under the Drugs Act 1940 and related rules are the principal domestic tools used to protect public safety.Import and export: procedural considerations
Imports of drugs and cosmetics are governed by the Import Policy Order 2021-2024 as at the date of the source material, which specifies prohibited or restricted items and sets conditions for clearance. Export operations are influenced by the Export Policy 2024-2027. In practice, importers are required to coordinate product registration, provide product samples and certificates of analysis, and satisfy customs documentation requirements under the Customs Act 1969. Import payments and foreign currency transactions are subject to the Foreign Exchange Regulation Act 1947 and banking rules under the Bank Company Act 1991.Exporters seeking to access foreign markets should be familiar with destination country registration requirements and commercial terms. Documentary credits and guarantees are commonly structured under internationally recognised practices such as UCP 600 for documentary credits and URDG 758 for demand guarantees; trade parties may also use INCOTERMS 2020 to allocate risks and responsibilities in cross-border shipments.Commercial interface and related laws
Drugs and cosmetics regulation does not operate in isolation. Corporate structuring, secured transactions over movable property, contract law, banking and finance, and intellectual property rights frequently intersect with regulatory compliance. For example, the Secured Transactions (Movable Property) Act 2023 is a modern framework for secured lending over movable assets and may be relevant where inventory financing or trade financing is involved. Similarly, the Code of Civil Procedure 1908 and the Negotiable Instruments Act 1881 are procedural touchpoints for commercial disputes involving contracts, payments or enforcement of securities.Common compliance challenges
Practitioners and businesses commonly face a number of recurring compliance challenges, including:- Keeping licensing and product registrations current in the face of regulatory updates.
- Ensuring supply chain quality and traceability to prevent substandard or counterfeit goods entering the market.
- Navigating import restrictions and customs valuation procedures that affect clearance timelines and costs.
- Managing cross-border transactional risk, including payment security and documentary compliance under UCP 600/URDG 758.
- Complying with evolving e-commerce and digital sales channels for drugs and cosmetic products.
Enforcement and dispute resolution
The DGDA exercises inspection and enforcement powers including product seizure and administrative sanctions under the Drugs Act 1940 and related rules. Disputes that arise from administrative action, product liability, contract performance or intellectual property claims may be addressed by negotiation, mediation, arbitration or litigation. Contractual parties often specify arbitration or other ADR procedures for commercial disputes; where parties litigate, domestic courts apply procedural law such as the CPC 1908 for civil disputes. Political, procedural and evidential factors in contested regulatory matters mean outcomes are fact-specific; when regulatory enforcement is threatened or initiated, affected parties commonly seek legal representation to navigate both administrative and judicial processes.Digitalisation, e-commerce and supply chain considerations
Digital marketplaces and online pharmacies create new compliance challenges because they expand channels through which drugs and cosmetics are marketed and sold. Regulatory frameworks and enforcement practices are adapting to manage online sales, consumer complaints and counterfeit risks. From a supply-chain perspective, manufacturers and exporters increasingly must demonstrate conformity with international quality standards and certifications to remain competitive in export markets.Practical compliance checklist
The checklist below sets out common practical steps that a business should consider when planning or conducting activity in the drugs and cosmetics sector in Bangladesh. This checklist is indicative and not exhaustive; it is drawn from the statutory and policy framework outlined above.- Confirm product classification: determine whether a product is regulated as a drug, a cosmetic or another category under the Drugs Act 1940 and accompanying rules.
- Check import/export policy status: review the Import Policy Order 2021-2024 or Export Policy 2024-2027 for any restrictions or special conditions affecting the product.
- Secure required licences: apply for manufacturing, import, wholesale or retail licences from the DGDA as appropriate before commencing activity;
- Prepare registration dossier: assemble formulation details, safety and stability data, labelling proposals and any clinical or analytical evidence needed for DGDA review.
- Arrange premises and technical staff: ensure premises meet storage and manufacturing standards and that suitably qualified personnel are available for regulatory inspections.
- Engage with customs and banks: coordinate documentation for customs clearance and confirm foreign exchange and payment arrangements under prevailing banking rules.
- Implement quality systems: develop GMP-aligned procedures, batch records, traceability and recall processes for post-market surveillance readiness.
- Draft commercial contracts carefully: include clear terms on quality specifications, delivery (INCOTERMS 2020), payment security (UCP 600/URDG 758 where used) and dispute resolution mechanisms.
- Monitor regulatory updates: periodically review DGDA notices, import/export policy updates and customs guidance for changes that affect operations.
- Plan for online sales compliance: if selling through e-commerce, map the additional requirements for online pharmacies or cosmetic platforms and the mechanisms for consumer complaints and returns.
Dispute prevention and response
Preventive measures reduce the likelihood and potential impact of regulatory or commercial disputes. Key preventive steps include robust supplier qualification and audit programs; clear contractual allocation of responsibilities and remedies; regular licence and registration audits; and documented GMP and quality assurance processes. If a dispute arises with a regulator, commercial counterparty or customs authority, early engagement and careful preservation of records, product samples and transactional documents are essential. Parties often consider ADR pathways such as mediation or arbitration to achieve a timely commercial resolution; where matters require court intervention, the procedural statutes cited above apply.International and future-facing considerations
The drugs and cosmetics sector in Bangladesh is increasingly influenced by international harmonisation of standards and trade practices. References to international frameworks in the sector — such as practice under INCOTERMS 2020 for delivery terms, UCP 600 and URDG 758 for trade finance or general harmonisation initiatives under international organisations — reflect the cross-border nature of pharmaceutical and cosmetic trade. Authorities and market participants are also monitoring the impact of digital commerce, supply-chain resilience and enhanced post-market surveillance approaches. Stakeholders should expect continued evolution in policy and operational practice.When to seek specialised assistance
Legal and regulatory issues in this sector can be highly fact-specific. For matters that require detailed regulatory submissions, contested enforcement responses, complex cross-border trade documentation or tailored contract drafting, businesses commonly obtain professional legal or regulatory advice. TRW Law Firm is a full-service international law firm based in Dhaka. We bring together 220+ lawyers and legal professionals.For further information about how advisory services may support compliance, users can review organisational information or contact appropriate service pages on the firm website: /our-firm/, /our-practices/, /services/. To request a meeting or an initial consultation, use the Book consultation link: Book consultation, or send an email to info@trw.org. General enquiries or to reach our office for directions can be made via /contact/.FAQ
1. What is the legal scope of the drugs and cosmetics law in Bangladesh?
Answer: Based on the commonly referenced statutes, the drugs and cosmetics legal regime governs the manufacture, import, export, distribution and sale of pharmaceutical and cosmetic products. The primary reference law is the Drugs Act 1940 with detailed procedures in the Drugs (Control) Ordinance and the Drugs (Control) Rules 1982. For specific product classification and regulatory scope, consultees should review those instruments or seek tailored guidance from the DGDA.2. How can a business obtain a manufacturing licence for drugs or cosmetics?
Answer: Under the licensing framework applied by the DGDA, a business typically applies with documentation on premises, technical staff and manufacturing processes, and must satisfy inspections that assess GMP compliance. Because procedural requirements may vary by product and change over time, applicants should consult the DGDA’s current guidance when preparing a submission.3. What import controls apply to drugs and cosmetics?
Answer: Imports are governed by the Import Policy Order (the source material referenced the Import Policy Order 2021-2024) and customs law under the Customs Act 1969. Importers commonly need product registration with the DGDA, certificates of analysis, and customs documentation for clearance. Import requirements can differ by product category and over time, so importers should verify the current policy lists and DGDA requirements before shipment.4. How does enforcement proceed when regulators identify substandard or counterfeit products?
Answer: The DGDA has powers to conduct inspections, carry out quality testing and seize products under the Drugs Act 1940 and related rules. Administrative actions such as seizure, suspension of licences or prosecution may follow depending on findings. Affected parties typically have procedural options to respond, and outcomes will depend on the evidence and applicable law in each case.5. What dispute resolution options are available for commercial or regulatory disputes?
Answer: Parties may pursue negotiation, mediation, arbitration or litigation. Many commercial contracts in cross-border trade also use internationally recognised documentary and dispute resolution frameworks such as UCP 600 for letters of credit and arbitration clauses for contractual disputes. The choice of forum and procedure often depends on the contract terms and the nature of the dispute.6. Are online sales of drugs and cosmetics regulated differently?
Answer: The source material indicates that e-commerce raises regulatory challenges and that authorities are developing frameworks to regulate online pharmacies and cosmetic sellers. Businesses selling online should assess additional compliance obligations for digital sales channels and monitor any guidance issued by regulatory authorities concerning online distribution.7. What international standards or instruments commonly affect trade in drugs and cosmetics?
Answer: International trade instruments and practices mentioned in commonly cited materials include INCOTERMS 2020 (for allocating shipping responsibilities), UCP 600 and URDG 758 (for documentary credits and guarantees). Exporters seeking international market access also consider destination country registration and certification requirements. For precise application to a particular transaction or market, parties should consult trade finance specialists and the destination country’s regulatory authority.8. Where can businesses find current official information on regulatory requirements?
Answer: Official and current information is typically available from the DGDA for licensing and product registration questions, and from the National Board of Revenue and Bangladesh Customs for import-export and tariff matters. Import and export policy details are published in the relevant Import Policy Order and Export Policy documents; those sources should be consulted for up-to-date requirements.Next steps and practical contacts
If you are planning market entry, a manufacturing project, or an import-export operation involving drugs or cosmetics, consider these initial steps:- Map your product against the statutory definitions under the Drugs Act 1940 and related rules to confirm whether a licence or registration is required.
- Review the current Import Policy Order or Export Policy for any product-specific restrictions.
- Prepare facility documentation and staffing evidence for DGDA inspections if undertaking manufacturing or wholesale activities.
- Confirm documentary requirements with your bank and customs broker to align payment instruments and customs clearance processes with DGDA registration timelines.
- Where appropriate, seek tailored legal or regulatory support early in planning to reduce the risk of delayed clearances, enforcement action or commercial dispute.
CONTINUE EXPLORINGConnected
Connected
legal insight.
Let’s discuss
the detail.
For a focused conversation with TRW, book a consultation or contact the firm directly.Book consultation →info@trw.org